Rare disease

Diffuse large B-cell lymphoma refractory

14 clinical trials

Quick filters

Clinical trials for Diffuse large B-cell lymphoma refractory

14 trials across Europe

See all trials →

Quick filters

14 Clinical trials

Diffuse large B-cell lymphoma refractory+1

Recruiting

Registered drugNo placebo

Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Chronic lymphocytic leukaemia refractory+13

Recruiting

Registered drugNo placebo

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:BGB-16673
Sponsor:BeOne Medicines AG

Contact Research Centre

Diffuse large B-cell lymphoma refractory

Recruiting

Registered drugNo placebo

Study to Optimize Cytokine Release Syndrome for Glofitamab with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Diffuse large B-cell lymphoma refractory+2

Recruiting

InvestigationalNo placebo

Study on the Effectiveness and Safety of AZD0486 for Adults with Relapsed or Refractory Non-Hodgkin Lymphoma

InvestigationalNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
Sponsor:AstraZeneca AB

Contact Research Centre

Diffuse large B-cell lymphoma refractory

Not yet recruiting

Registered drugNo placebo

Study Comparing R-MINI-CHOP and R-MINI-CHP with Polatuzumab Vedotin for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older or Frail Patients Aged 75 and Older

Registered drugNo placebo

Denmark

Participants:65+ years
Substances:Cyclophosphamide
Sponsor:Region Skane

Contact Research Centre

Diffuse large B-cell lymphoma refractory

Not recruiting

Registered drugNo placebo

A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

See all trials →

Diffuse large B-cell lymphoma refractory

Clinical trials for Diffuse large B-cell lymphoma refractory

Diffuse large B-cell lymphoma refractory+1

Glofitamab plus drug combination for relapsed/refractory large B‑cell lymphoma in high‑risk second‑line patients eligible for CAR‑T therapy

Chronic lymphocytic leukaemia refractory+13

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

Diffuse large B-cell lymphoma refractory

Study to Optimize Cytokine Release Syndrome for Glofitamab with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse large B-cell lymphoma refractory+2

Study on the Effectiveness and Safety of AZD0486 for Adults with Relapsed or Refractory Non-Hodgkin Lymphoma

Diffuse large B-cell lymphoma refractory

Study Comparing R-MINI-CHOP and R-MINI-CHP with Polatuzumab Vedotin for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older or Frail Patients Aged 75 and Older

Diffuse large B-cell lymphoma refractory

A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.